Top Rule Breakers Seek Innovation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ORCL?
Source: Fool
- Vertex Drug Trial Success: Vertex Pharmaceuticals (VRTX) rose over 5% after the closing bell due to positive trial data from Povetacicept, enhancing the likelihood of a potential accelerated FDA approval filing, which is expected to further boost the company's stock performance, surpassing a 33% increase over the S&P 500 since February 2022.
- Hewlett Packard's Strong Earnings: Hewlett Packard (HPE) gained over 1% thanks to a 380% surge in Data Center Networking sales and an upgraded group revenue forecast, indicating robust growth potential in the market that may attract more investor interest.
- Casey's and Vail Resorts Earnings Pressure: Casey's General Stores (CASY) dropped about 2% ahead of the opening bell due to only a 0.5% revenue increase, while Vail Resorts (MTN) fell after reporting a 5% quarterly revenue drop, with the CEO citing weather impacts, highlighting challenges faced by the industry.
- BioNTech Faces Losses: BioNTech (BNTX) fell over 14% ahead of the opening bell as it reported an annual net loss nearly double that of the previous year and announced plans for co-founders to create an independent company focusing on next-generation mRNA innovations, which may affect its future market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORCL
Wall Street analysts forecast ORCL stock price to rise
34 Analyst Rating
25 Buy
9 Hold
0 Sell
Moderate Buy
Current: 151.560
Low
180.00
Averages
309.59
High
400.00
Current: 151.560
Low
180.00
Averages
309.59
High
400.00
About ORCL
Oracle Corporation offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. The Company operates through three businesses: cloud and license, hardware and service. Its cloud and license business is engaged in the sale, marketing and delivery of its enterprise applications and infrastructure technologies through cloud and on-premise deployment models including its cloud services and license support offerings, and its cloud license and on-premise license offerings. Its hardware business provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management and other hardware-related software to support diverse IT environments. Its services business provides services to customers and partners to help maximize the performance of their investments in Oracle applications and infrastructure technologies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Revenue Growth Expectations: Analysts anticipate Oracle's Q3 revenue to reach $16.9 billion, a 19% increase from $14.13 billion in the same quarter last year, indicating the company's ongoing expansion in the cloud computing sector and strong market demand.
- Strong Profitability: Despite Oracle missing revenue estimates in 8 of the last 10 quarters, its profit performance has been robust, exceeding earnings expectations in the last three quarters, demonstrating effective strategies in cost control and profit enhancement.
- Cloud Services Contract: Oracle secured a deal with the Centers for Medicare & Medicaid Services to migrate critical systems to its cloud platform, further solidifying its position in the government cloud services market while adhering to strict federal security standards.
- Defense Contract Expansion: Oracle won an $88 million task order from the U.S. Air Force to provide cloud services for highly sensitive workloads, showcasing the company's competitiveness and market confidence in securing government and enterprise infrastructure contracts.
See More
- Data Center Progress: Oracle confirmed that its flagship AI data center in Abilene, Texas, is operational with 200MW, and despite challenges with the expansion plans alongside OpenAI, the company asserts that progress is on track, alleviating market concerns about the future of its data centers.
- Financial Expectations: Analysts anticipate Oracle's third-quarter revenue to rise nearly 20% to $16.9 billion, marking the best growth rate in three years, although the company faces increasing debt and risks associated with reliance on a small group of customers.
- Debt Pressure: Oracle is piling on massive debt to fund new data center builds, planning to raise up to $50 billion this year through debt and equity financing, which has raised investor concerns, particularly given the company's performance is heavily reliant on a single customer.
- Market Reaction: Despite Oracle's stock price dropping over 53% since September 10, 32 out of 43 analysts still rate it as 'Buy' or higher, indicating cautious optimism in the market regarding its future growth, especially in the context of AI-driven revenue acceleration.
See More
- Vertex Drug Trial Success: Vertex Pharmaceuticals (VRTX) rose over 5% after the closing bell due to positive trial data from Povetacicept, enhancing the likelihood of a potential accelerated FDA approval filing, which is expected to further boost the company's stock performance, surpassing a 33% increase over the S&P 500 since February 2022.
- Hewlett Packard's Strong Earnings: Hewlett Packard (HPE) gained over 1% thanks to a 380% surge in Data Center Networking sales and an upgraded group revenue forecast, indicating robust growth potential in the market that may attract more investor interest.
- Casey's and Vail Resorts Earnings Pressure: Casey's General Stores (CASY) dropped about 2% ahead of the opening bell due to only a 0.5% revenue increase, while Vail Resorts (MTN) fell after reporting a 5% quarterly revenue drop, with the CEO citing weather impacts, highlighting challenges faced by the industry.
- BioNTech Faces Losses: BioNTech (BNTX) fell over 14% ahead of the opening bell as it reported an annual net loss nearly double that of the previous year and announced plans for co-founders to create an independent company focusing on next-generation mRNA innovations, which may affect its future market performance.
See More
- Oracle Earnings Focus: Oracle is set to report its Q3 earnings on Wednesday, with market expectations high for updates on its artificial intelligence developments, which could significantly influence industry trends.
- NIO's First Profit: NIO reported Q4 revenue of 34.6 billion yuan (approximately $5 billion), exceeding estimates, although its quarterly profit of $0.05 per share slightly missed expectations, marking the company's first net profit and showcasing its competitiveness in the EV market.
- Kohl's Sales Decline: Kohl's experienced a 2.8% decline in same-store sales, worse than the expected 1.7% drop, despite reporting earnings per share of $1.07, which surpassed the $0.89 estimate, indicating pressure on sales during the holiday season.
- Hewlett Packard Enterprise Growth: Hewlett Packard Enterprise beat Q2 revenue estimates, driven by strong demand for AI infrastructure, raising its adjusted earnings per share forecast to $2.30-$2.50, reflecting robust market demand.
See More
- Financing Impact: Oracle's announcement of a $50 billion financing plan in early February, which includes a $5 billion convertible preferred offering and approximately $25 billion in senior notes, highlights strong demand for its data center expansion but raises concerns about the pace of dilution for shareholders.
- Collaboration with OpenAI: Although talks to expand its deal with OpenAI in Texas fell through, Oracle is still on track to deliver eight data centers to OpenAI, ensuring its competitive position in the AI cloud computing space, particularly in maintaining strong relationships with key customers.
- Market Sensitivity: The news of Oracle's $300 billion deal with OpenAI previously boosted its stock by 35% last September, but subsequent debt increases have raised investor concerns about its financial health, leading to a widening of its five-year credit default swaps, reflecting skepticism about its investment-grade credit rating.
- Cost Control Measures: Analysts speculate that Oracle may implement workforce reductions and divestitures to address financing issues, with potential layoffs of 20,000 to 30,000 employees expected to generate $8 to $10 billion in incremental free cash flow, indicating urgency in cost management.
See More
- Financing Overview: Oracle announced a $50 billion financing plan last month to support its data center buildout, with increasing market concern over the pace of dilution for shareholders, as analysts emphasize the importance of financing cadence.
- Debt Financing Details: The latest financing measures include a $5 billion convertible preferred offering and approximately $25 billion in senior notes with varying maturities, indicating strong market demand for Oracle, although investors remain cautious about its financial health.
- Collaboration with OpenAI: Oracle's relationship with OpenAI is under scrutiny; despite failed negotiations to expand in Texas, the delivery of eight sites to OpenAI remains on schedule, which is crucial for investor confidence.
- Market Reaction and Future Outlook: The news of Oracle's $300 billion deal initially boosted its stock by 35%, but subsequent debt increases raised concerns about its financial stability, leading analysts to speculate that the company may consider layoffs and divestitures to address financing challenges.
See More










